Academic Meeting of Domestic and Overseas Experts — SANBEXIN^® Opens the Door to Brain Cell Protection

XIANNUOXIN^®: The Key to Pandemic Prevention and Control for Vulnerable Populations

NMPA Commissioner Jiao Hong Investigated the Quality Assurance and Supply Guarantee of the Anti-COVID-19 Innovative Drug XIANNUOXIN^®

COSELA^®, the first and only proactive multilineage myeloprotection therapy for chemotherapy-induced myelosuppression, was launched in China, greatly improving the accessibility of imported drugs urgently needed in clinical practice

XIANNUOXIN^® is put into production and launched today, contributing to China's economic development and the public's health

Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA^® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Simcere Zaiming Enrolls First Patient in Phase 1 Trial of SIM0237, an anti-PD-L1/IL-15 Bi-functional Fusion Protein

Another Milestone for Simcere Zaiming! China Has Its First Prescription for COSELA^®: The First and Only Proactive Multilineage Myeloprotection Therapy for Chemotherapy-Induced Myelosuppression

XIANNUOXIN^® - The First Chinese 3CL Anti-COVID-19 Drug - Receives Approval from the NMPA

Innovative, Potential Best-in-Class, Anti-COVID-19 Drug, XIANNUOXIN^® has Received an Accepted New Drug Application from the NMPA